Adze Biotechnology Submits Bellberry HREC Application for Adze1.C Clinical Trial in Australia
Adze Biotechnology, Inc., a preclinical-stage biopharmaceutical company pioneering novel oncolytic immunotherapies for cancer treatment, announced today the submission of a Human Research Ethics Committee (HREC) application to Bellberry Limited in Australia for the company’s Phase 1 clinical trial of Adze1.










